Spinogenix awarded $1M to advance clinical testing of SPG302
Spinogenix has won a nearly $1 million grant from the U.S. Department of Defense (DoD) to move ahead with…
Articles by Margarida Maia, PhD
Dosing of healthy adults begins in Phase 1 study of oral CVN293
A first healthy volunteer has been dosed in a Phase 1 clinical study evaluating how safe and well tolerated is…
New deal aims to bring edaravone for ALS to Australia, New Zealand
Note: This story was updated Sept. 25, 2023, to correct that TW001 uses the same active ingredient as Radicava and…
More evidence needed to support use of high-calorie diet for ALS
While eating a high-calorie diet is safe and well tolerated, it does not appear to slow disease progression or reduce…
ALS therapy target: Integrin that spurs immune cells to ‘eat’ neurons
A “velcro-like” protein called alpha-5 integrin consistently is found at high levels in immune cells near motor neurons being damaged…
InSilicoTrials, Axoltis partner to work on potential ALS therapy
InSilicoTrials and Axoltis Pharma are teaming up to advance the development of NX210c, the latter’s lead candidate for…
Researcher awarded $10K to advance work on ALS therapy
A professor at Massachusetts General Hospital and Harvard Medical School was awarded $10,000 by Mass General Brigham (MGB) for…
ATH-1105 protects against common ALS, FTD disease mechanisms
Athira Pharma’s experimental therapy ATH-1105 shows anti-inflammatory and neuroprotective effects, promoting neuron growth and reducing damage associated with mechanisms…
Study uncovers 2 therapies to help target autoimmune inflammation
Dimethyl fumarate (DMF) — an oral medication approved for multiple sclerosis — and H-151, an experimental treatment, can suppress…
Slower ALS progression evident with lower NfL levels: NurOwn trial
NurOwn, an experimental treatment, significantly lowered neurofilament light chain (NfL) levels in the spinal fluid, a marker of nerve…